Raymond James Financial Inc. Takes Position in Phreesia, Inc. (NYSE:PHR)

Raymond James Financial Inc. acquired a new stake in Phreesia, Inc. (NYSE:PHR - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 15,056 shares of the company's stock, valued at approximately $379,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of PHR. Franklin Resources Inc. raised its holdings in shares of Phreesia by 3.0% in the 3rd quarter. Franklin Resources Inc. now owns 1,497,631 shares of the company's stock worth $31,495,000 after acquiring an additional 42,973 shares during the last quarter. State Street Corp raised its stake in shares of Phreesia by 7.1% in the third quarter. State Street Corp now owns 1,327,586 shares of the company's stock worth $30,256,000 after purchasing an additional 88,517 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Phreesia by 4.7% in the third quarter. Geode Capital Management LLC now owns 1,245,797 shares of the company's stock valued at $28,397,000 after purchasing an additional 55,934 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Phreesia by 10.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 493,448 shares of the company's stock valued at $12,415,000 after buying an additional 46,209 shares during the last quarter. Finally, Peregrine Capital Management LLC grew its holdings in Phreesia by 0.8% during the fourth quarter. Peregrine Capital Management LLC now owns 319,327 shares of the company's stock worth $8,034,000 after buying an additional 2,531 shares in the last quarter. Institutional investors own 92.10% of the company's stock.

Phreesia Stock Performance

NYSE:PHR traded up $0.06 during trading hours on Friday, reaching $24.06. The stock had a trading volume of 472,952 shares, compared to its average volume of 434,045. The stock has a market cap of $1.41 billion, a P/E ratio of -16.37 and a beta of 0.82. The stock has a 50 day simple moving average of $26.57 and a 200 day simple moving average of $24.27. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.74 and a current ratio of 1.74. Phreesia, Inc. has a 12-month low of $17.07 and a 12-month high of $30.53.

Insider Buying and Selling

In other Phreesia news, CFO Balaji Gandhi sold 5,827 shares of the business's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $27.31, for a total transaction of $159,135.37. Following the sale, the chief financial officer now owns 141,846 shares of the company's stock, valued at $3,873,814.26. The trade was a 3.95 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Evan Roberts sold 1,785 shares of the stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $26.98, for a total value of $48,159.30. Following the sale, the chief operating officer now directly owns 768,208 shares in the company, valued at $20,726,251.84. This trade represents a 0.23 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 176,963 shares of company stock valued at $4,920,321. 5.80% of the stock is owned by insiders.

Analyst Ratings Changes

Several brokerages have weighed in on PHR. Royal Bank of Canada upgraded Phreesia from a "sector perform" rating to an "outperform" rating and raised their price objective for the company from $24.00 to $32.00 in a research note on Wednesday, January 8th. Citigroup raised their price target on shares of Phreesia from $31.00 to $35.00 and gave the company a "buy" rating in a research report on Friday, January 10th. Needham & Company LLC reaffirmed a "buy" rating and issued a $29.00 price objective on shares of Phreesia in a research report on Thursday, March 13th. KeyCorp lifted their target price on shares of Phreesia from $28.00 to $30.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 8th. Finally, Canaccord Genuity Group boosted their target price on Phreesia from $34.00 to $35.00 and gave the stock a "buy" rating in a research note on Thursday, March 13th. Twelve analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $31.33.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.